RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay Medical, Inc. continues to broaden medical center acceptance of Cesium-131 as a brachytherapy treatment for prostate cancer, adding 51 active sites for a total of 142 through March 23, 2007. These active sites are either revenue producing, in the process of getting licensed for Cesium-131, or are targeted and are in advanced discussions to adopt Cesium-131.
